The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-basedtopicalformulations for reducing oxidative stress and inflammation.
The conversation discusses creating a personalized topical treatment for hair loss, with ingredients like finasteride, minoxidil, tretinoin, melatonin, caffeine, and others. Users share their ideal formulations, including combinations of minoxidil, finasteride, tretinoin, adenosine, and other compounds, while also discussing the importance of managing inflammation.
Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.
Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hair follicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.